Do TNFSF13B (BAFF) genetic variants increase autoimmune risk by raising BAFF signaling?

Genetic variations in the TNFSF13B gene, which encodes the B-cell-activating factor (BAFF), are robustly linked to increased autoimmune susceptibility through a well-defined mechanistic pathway that bypasses immune tolerance.

Genetic drivers of BAFF overexpression

The most significant genetic driver is a specific variant known as BAFF-var (rs115527007 or associated rs9514828). This variant alters the 3' untranslated region (3'UTR) of the TNFSF13B gene, creating an alternative polyadenylation site.

• mRNA Stability: The resulting shorter mRNA transcript lacks the binding site for microRNA-15a (miR-15a), which typically recruits proteins like nuclear factor 90 (NF90) to suppress translation.
• Elevated Levels: By escaping this microRNA-mediated degradation, the BAFF-var transcript is translated more efficiently. This leads to significantly higher circulating serum BAFF levels—in some cases nearly double the median levels of non-carriers.

Mechanisms of B-cell tolerance escape

Elevated BAFF signaling acts as a critical survival signal that disrupts normal immune checkpoints.

• Survival Pathways: BAFF binds to its receptors (BAFF-R, TACI, and BCMA), activating both canonical and non-canonical NF-κB pathways. This upregulates anti-apoptotic proteins, such as Bcl-2, which protect B cells from programmed cell death.
• Bypassing Tolerance: Under normal conditions, autoreactive B cells are deleted or rendered anergic (unresponsive). However, high BAFF concentrations lower the threshold for B-cell selection, allowing these self-reactive clones to survive, mature into transitional B cells, and eventually differentiate into antibody-producing plasma cells.
• Metabolic Support: BAFF signaling also promotes metabolic reprogramming via mTORC1 and GLUT1, sustaining the hyperactivation of these pathogenic B-cell populations.

Clinical evidence of autoimmune risk

Large-scale genome-wide association studies (GWAS) and meta-analyses have confirmed that these genetic variants significantly increase the risk of several autoimmune conditions, particularly in populations where B-cell dysregulation is a hallmark.

• Disease Associations: The BAFF-var variant is strongly associated with systemic lupus erythematosus (SLE) (OR ~1.2-1.3) and rheumatoid arthritis (RA) (p = 0.002, OR = 1.24). It is also a documented risk factor for multiple sclerosis (MS) and Graves’ disease.
• Biomarkers: In patients with SLE, higher BAFF levels correlate directly with increased disease activity (SLEDAI scores) and higher titers of anti-dsDNA autoantibodies.
• Therapeutic Validation: The clinical success of BAFF-inhibiting therapies, such as belimumab and telitacicept, provides "reverse" validation that targeting this pathway reduces autoantibody production and improves clinical outcomes.

Bottom line

Genetic variation in TNFSF13B is a well-supported cause of increased BAFF signaling. This elevation allows autoreactive B cells to escape immune checkpoints and survive, significantly increasing the risk of developing B-cell-mediated autoimmune diseases like SLE and RA.